Views & Analysis | Perspectives on pharma industry issues

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Articles

Healthcare markets in Asia: updates on the medical device ma...

Ames Gross provides an update on the Vietnamese medical device industry, concluding his series on the healthcare markets in Asia. With its 87 million people and a fast growing economy, the healthcare market in Vietnam is growing. The Vietnamese government...

Articles

mHealth Monthly Mashup: release 16.0 – what “responsive desi...

This month’s mashup takes a look at the latest trend in mobile technology, and considers implications for pharma… Technologists, despite their almost religious faith in transcendent reason and geeky cleverness, are hardly immune to irrational…

Articles

How can pharmaceutical companies engage with patients? Lesso...

Eileen O’Brien shares her thoughts on how pharma marketers can build better relationships with patients, looking at the lessons pharma can learn from rare disease brands. If information is power, then the Internet and social media have enabled a huge power shift in healthcare into...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access